

**A. For Equity Issues**

|                          |                                                      |
|--------------------------|------------------------------------------------------|
| Type of issue (IPO/ FPO) | Initial Public Offering (IPO) on SME Platform of BSE |
|--------------------------|------------------------------------------------------|

|                                                           |                                                                                                                                                  |
|-----------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Grade of issue alongwith name of the rating agency</b> | Since the issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, there is no requirement of appointing a IPO Grading agency. |
|-----------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|

QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges (See Clause 35 of the listing agreement)

|                                                                               |     |
|-------------------------------------------------------------------------------|-----|
| (ii) at the end of the 1st Quarter immediately after the listing of the issue | Nil |
|-------------------------------------------------------------------------------|-----|

|                           |     |
|---------------------------|-----|
| (iv) at the end of 2nd FY | NIL |
|---------------------------|-----|

*\*Will be updated once the company makes necessary disclosures on the website of BSE Ltd.*

| Parameters                              | (Rs. in Lakhs)   |                                             |                                             |
|-----------------------------------------|------------------|---------------------------------------------|---------------------------------------------|
|                                         | 1st FY (2025-26) | 2nd FY (2026-27)                            | 3rd FY (2027-28)                            |
| Income from operations                  | 4,670.81         |                                             |                                             |
| Net Profit for the period               | 461.99           | Will update the same at the end of 2nd Year | Will update the same at the end of 3rd Year |
| Paid-up equity share capital            | 686.00           |                                             |                                             |
| Reserves excluding revaluation reserves | 1,648.62         |                                             |                                             |

|                           |                                             |
|---------------------------|---------------------------------------------|
| (ii) at the end of 2nd FY | Will update the same at the end of 2nd Year |
|---------------------------|---------------------------------------------|

|                            |                                             |
|----------------------------|---------------------------------------------|
| (iii) at the end of 3rd FY | Will update the same at the end of 3rd Year |
|----------------------------|---------------------------------------------|

|                          |           |
|--------------------------|-----------|
| (i) at the end of 1st FY | No change |
|--------------------------|-----------|

|                            |                                             |
|----------------------------|---------------------------------------------|
| (ii) at the end of 2nd FY  | Will update the same at the end of 2nd Year |
| (iii) at the end of 3rd FY | Will update the same at the end of 3rd Year |

| Objects of the issue (Rs in Lacs)                                           | as disclosed in the offer document | Actual implementation* | (Rs. in Lacs)<br>Reasons for delay in implementation, if any |
|-----------------------------------------------------------------------------|------------------------------------|------------------------|--------------------------------------------------------------|
| Capital Expenditure for Office Premises with furniture and Industrial Racks | 162.95                             | 162.95                 | NA                                                           |
| Working Capital                                                             | 800.00                             | 800.00                 |                                                              |
| General corporate purposes                                                  | 191.05                             | 191.05                 |                                                              |
| TOTAL                                                                       | 1,154.00                           | 1,154.00               |                                                              |

\* Source: BSE filing Reg 32(1) of SEBI(LODR) Reg, 2015

|                                        | (Rs. In Lacs) |
|----------------------------------------|---------------|
| (i) as disclosed in the offer document | 1,154         |
| (ii) Actual utilization                | 1,154         |
| (iii) Reasons for deviation, if any    | NA            |

|                                                                                                                             |                                                                                |
|-----------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| (a) <i>Comments on use of funds</i>                                                                                         | Proceeds have been utilized as per the objects mentioned in the offer document |
| (b) <i>Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document</i> | nil                                                                            |
| (c) <i>Any other reservations expressed by the monitoring agency about the end use of funds</i>                             | nil                                                                            |
| <i>(To be submitted till the time the issue proceeds have been fully utilised)</i>                                          |                                                                                |

|                   |    |
|-------------------|----|
| Issue price (Rs): | 70 |
|-------------------|----|

\*No sectoral Index available

*Basis for Issue Price and Comparison with Peer Group & Industry Average (Source of accounting ratios of peer group and industry average may be indicated; source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)*

| Accounting ratio                     | Name of company                 | As disclosed in the offer document<br>(See Clause (2) (VII) (K) of Schedule VIII to SEBI (ICDR) Regulations, 2009) | At the end of 1st FY | At the end of 2nd FY | At the end of 3rd FY |
|--------------------------------------|---------------------------------|--------------------------------------------------------------------------------------------------------------------|----------------------|----------------------|----------------------|
| EPS                                  | APTUS PHARMA LIMITED            | 5.32                                                                                                               | 7.78                 |                      |                      |
|                                      | Zota health care limited        | 3.16                                                                                                               | -22.46               |                      |                      |
|                                      | Sunrest Lifescience Limited     | 4.66                                                                                                               | 9.59                 |                      |                      |
|                                      | Lincoln Pharmaceuticals Limited | 41.11                                                                                                              | 43.88                |                      |                      |
|                                      | Industry Avg:                   | 16.31                                                                                                              | 10.34                |                      |                      |
|                                      | APTUS PHARMA LIMITED            | 13.16                                                                                                              | 44.88                |                      |                      |
| P/E                                  | Zota health care limited        | 382.12                                                                                                             | -47.41               |                      |                      |
|                                      | Sunrest Lifescience Limited     | 10.56                                                                                                              | 3.86                 |                      |                      |
|                                      | Lincoln Pharmaceuticals Limited | 13.53                                                                                                              | 12.86                |                      |                      |
|                                      | Industry Avg:                   | 135.40                                                                                                             | -10.23               |                      |                      |
| RoNW                                 | APTUS PHARMA LIMITED            | 44.50                                                                                                              | 19.79                |                      |                      |
|                                      | Zota health care limited        | 2.72                                                                                                               | -10.64               |                      |                      |
|                                      | Sunrest Lifescience Limited     | 12.36                                                                                                              | 39.14                |                      |                      |
|                                      | Lincoln Pharmaceuticals Limited | 12.26                                                                                                              | 11.60                |                      |                      |
|                                      | Industry Avg:                   | 9.11                                                                                                               | 13.37                |                      |                      |
|                                      | APTUS PHARMA LIMITED            | 13.93                                                                                                              | 34.03                |                      |                      |
| NAV per share based on balance sheet | Zota health care limited        | 110.83                                                                                                             | 201.01               |                      |                      |
|                                      | Sunrest Lifescience Limited     | 37.72                                                                                                              | 47.60                |                      |                      |
|                                      | Lincoln Pharmaceuticals Limited | 335.34                                                                                                             | 378.25               |                      |                      |
|                                      | Industry Avg:                   | 161.30                                                                                                             | 208.95               |                      |                      |
|                                      |                                 |                                                                                                                    |                      |                      |                      |

**Any other material information** Nil

**Note:**

- (i) Merchant Banker can give its comments on any of the above sections
- (ii) Merchant Banker may obtain information/ clarification from the issuer or stock exchange, wherever felt necessary
- (iii) In case any of the above reporting dates happens to be a holiday, the immediately following working day may be taken